Megace Es

Endometrial Neoplasms, Endometrial Neoplasms, Acquired Immunodeficiency Syndrome + 7 more

Treatment

7 Active Studies for Megace Es

What is Megace Es

Megestrol acetate

The Generic name of this drug

Treatment Summary

17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione is a hormone used to treat various conditions. It is usually prescribed in the form of an acetate ester and is more powerful than progesterone. It is used to suppress ovulation and as a way to manage certain types of breast cancer.

Megestrol Acetate

is the brand name

image of different drug pills on a surface

Megace Es Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Megestrol Acetate

Megestrol acetate

1988

76

Effectiveness

How Megace Es Affects Patients

Megestrol is a synthetic form of the hormone progesterone, which affects the endometrium, body temperature, and pituitary gland. It also has a small effect on glucocorticoid and mineralocorticoid hormones. This drug does not have any estrogenic, androgenic, or anabolic effects. The exact way it works to reduce appetite and cachexia (wasting) is unknown. It was originally developed as a contraceptive, but was later found to be useful in treating breast cancer.

How Megace Es works in the body

We don't know exactly how megestrol acetate works, but it likely has something to do with suppressing hormones that control appetite. It also seems to change how the body breaks down food, which may help explain why it causes weight gain. Megestrol may also interfere with hormones that prevent fat from being stored in the body.

When to interrupt dosage

The endorsed dosage of Megace Es relies upon the determined condition, including Recurrent Endometrial Carcinoma, Breast and Endometrial Carcinoma. The quantity of dosage fluctuates as per the method of delivery (e.g. Oral or Suspension - Oral) noted in the table beneath.

Condition

Dosage

Administration

Endometrial Neoplasms

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Endometrial Neoplasms

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Acquired Immunodeficiency Syndrome

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Palliative Treatment

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Anorexia

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Breast

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Endometrial Carcinoma

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Weight decreased

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Breast

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Breast

, 40.0 mg, 125.0 mg/mL, 40.0 mg/mL, 20.0 mg, 80.0 mg/mL, 160.0 mg, 625.0 mg/mL

Tablet - Oral, , Tablet, Oral, Suspension, Suspension - Oral

Warnings

Megace Es Contraindications

Condition

Risk Level

Notes

suspected pregnancy

Do Not Combine

There are 20 known major drug interactions with Megace Es.

Common Megace Es Drug Interactions

Drug Name

Risk Level

Description

Dofetilide

Major

Megestrol acetate may decrease the excretion rate of Dofetilide which could result in a higher serum level.

Tranexamic acid

Major

Megestrol acetate may increase the thrombogenic activities of Tranexamic acid.

Abacavir

Minor

Megestrol acetate may decrease the excretion rate of Abacavir which could result in a higher serum level.

Acetohexamide

Minor

The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Megestrol acetate.

Aclidinium

Minor

Megestrol acetate may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Megace Es Toxicity & Overdose Risk

Studies have not reported any serious side effects from taking megestrol acetate oral suspension in doses up to 1200 mg/day. Taking megestrol acetate, a drug that increases the appetite, can lead to suppression of the adrenal glands. This is thought to be due to the drug's effects on the body's cortisol production.

image of a doctor in a lab doing drug, clinical research

Megace Es Novel Uses: Which Conditions Have a Clinical Trial Featuring Megace Es?

315 active clinical trials are currently being conducted to assess the potential of Megace Es to reduce metastatic Endometrial Carcinoma, Cachexia and Breast Disease.

Condition

Clinical Trials

Trial Phases

Endometrial Neoplasms

0 Actively Recruiting

Endometrial Carcinoma

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Anorexia

1 Actively Recruiting

Phase 1

Breast

0 Actively Recruiting

Breast

0 Actively Recruiting

Breast

0 Actively Recruiting

Weight decreased

0 Actively Recruiting

Acquired Immunodeficiency Syndrome

4 Actively Recruiting

Phase 1, Phase 2, Not Applicable

Endometrial Neoplasms

0 Actively Recruiting

Megace Es Reviews: What are patients saying about Megace Es?

5

Patient Review

2/15/2008

Megace Es for Loss of Appetite with HIV

This drug is extremely effective. If you're struggling to maintain weight, this will help you out. The only downside is that it can make it harder to sleep at night.

4.3

Patient Review

9/16/2008

Megace Es for Decrease in Weight due to HIV Infection

I've been able to eat more since starting this treatment and I've already put on 15 pounds in less than two weeks.

4.3

Patient Review

12/8/2008

Megace Es for Metastatic Endometrial Carcinoma

Magace has, as advertised, increased my appetite. I'm now eating more and have even put on some weight. However, it also comes with the side effect of seriously increasing gas production. Not sure if the extra appetite is worth that!

1

Patient Review

4/18/2012

Megace Es for Cancer in the Lining of the Uterus

I've been taking Megace for nearly three weeks now to treat my endometrial cancer. I'm not sure if the side effects are worth the slim chance of it helping me cure my cancer. I've been experiencing extreme agitation, anxiety, inability to sleep at night, diarrhea, and increased appetite since starting this medication, which has lead to weight gain. I snap at everyone over EVERYTHING. I don't think this is going to work for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about megace es

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Megace Es

Image of New Jersey Community Research Initiative in Newark, United States.

AI-DBT for Suicide Prevention in HIV/AIDS

18+
All Sexes
Newark, NJ

One in four older persons living with HIV/AIDS (PLWHA) report at least one suicide attempt in their lifetime, and the risk for death by suicide is 100 times higher in PLWHA than in the general population. Currently, there are no behavioral interventions that specifically address suicide prevention for older PLWHA, despite their unique biopsychosocial and structural risk factors. Through this work, investigators will adapt Dialectical Behavior Therapy, an evidence-based intervention for suicide prevention, for patients with PLWHA to be delivered by an AI-powered conversational Agent developed by our industry partner, Empower Health. Investigators will then pilot test the feasibility, usability, acceptability and preliminary efficacy to improve self-efficacy to manage negative emotions in n=50 older adults living with HIV/AIDS.

Recruiting
Has No Placebo

New Jersey Community Research Initiative (+1 Sites)

Elissa Kozlov, PhD

Image of Los Angeles General Medical Center in Los Angeles, United States.

Decision Support Tool for HIV Treatment

18+
All Sexes
Los Angeles, CA

This study is testing software designed to help healthcare providers choose the best HIV treatment combinations for their patients. HIV medicines, known as antiretroviral therapy (ART), can be complex to manage because the right regimen depends on many factors-such as drug resistance, other health conditions, and medication schedules. Many people with HIV are cared for by general clinicians who may not have access to HIV specialists, which can make treatment decisions more challenging. In this study, healthcare providers will use patient cases to compare standard HIV treatment resources with a new clinical decision support tool that gives evidence-based ART recommendations at the point of care. The investigators hypothesize that using the tool will help providers select treatment plans that better match clinical guidelines, make decisions faster, reduce mental effort, and increase overall satisfaction with the prescribing process.

Waitlist Available
Has No Placebo

Los Angeles General Medical Center

Hayoun Lee, PhD

Image of MedStar Georgetown University Hospital in Washington, United States.

Palliative Care Interventions for Serious Illness

18+
All Sexes
Washington, United States

This stepped-wedge, cluster randomized pragmatic trial among 9 MedStar hospitals for patients with serious illness and unmet palliative care (PC) needs will test two interventions embedded within the electronic health record (EHR): (1) a PC needs triggered alert to opt-in to PC consults nudging hospital clinicians to order specialty PC consults for eligible inpatients, and (2) a palliative care needs triggered alert with an opt-out to palliative care consults. The trial will compare the interventions effects to usual care, focusing on completed PC consults during the hospital encounter and other secondary outcomes. The trial also includes an embedded mixed methods study to explore factors influencing the effectiveness and equity of intervention implementation.

Phase 3
Waitlist Available

MedStar Georgetown University Hospital (+10 Sites)

Michael Harhay, PhD, MPH

Have you considered Megace Es clinical trials?

We made a collection of clinical trials featuring Megace Es, we think they might fit your search criteria.
Go to Trials